文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期,新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

用于眼部延长局部药物递送的胶凝低渗聚合物溶液。

Gelling hypotonic polymer solution for extended topical drug delivery to the eye.

机构信息

Center for Nanomedicine at the Wilmer Eye Institute, Johns Hopkins University School of Medicine, Baltimore, MD, USA.

Department of Ophthalmology, Wilmer Eye Institute, Johns Hopkins University School of Medicine, Baltimore, MD, USA.

出版信息

Nat Biomed Eng. 2020 Nov;4(11):1053-1062. doi: 10.1038/s41551-020-00606-8. Epub 2020 Sep 7.


DOI:10.1038/s41551-020-00606-8
PMID:32895514
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7655548/
Abstract

Eye-drop formulations should hold as high a concentration of soluble drug in contact with ocular epithelium for as long as possible. However, eye tears and frequent blinking limit drug retention on the ocular surface, and gelling drops typically form clumps that blur vision. Here, we describe a gelling hypotonic solution containing a low concentration of a thermosensitive triblock copolymer for extended ocular drug delivery. On topical application, the hypotonic formulation forms a highly uniform and clear thin layer that conforms to the ocular surface and resists clearance from blinking, increasing the intraocular absorption of hydrophilic and hydrophobic drugs and extending the drug-ocular-epithelium contact time with respect to conventional thermosensitive gelling formulations and commercial eye drops. We also show that the conformal gel layer allows for therapeutically relevant drug delivery to the posterior segment of the eyeball in pigs. Our findings highlight the importance of formulations that conform to the ocular surface before viscosity enhancement for increased and prolonged ocular surface contact and drug absorption.

摘要

滴眼液制剂应在尽可能长的时间内保持与眼上皮接触的高浓度可溶性药物。然而,眼液和频繁的眨眼会限制药物在眼表面的滞留,而凝胶滴通常会形成团块,导致视力模糊。在这里,我们描述了一种包含低浓度温敏三嵌段共聚物的低渗凝胶溶液,用于延长眼部药物输送。局部应用时,低渗配方形成高度均匀且清晰的薄层,与眼表面一致,并能抵抗眨眼清除,增加亲水性和疏水性药物的眼内吸收,并延长药物与眼上皮的接触时间,与传统的温敏凝胶制剂和商业眼药水相比。我们还表明,这种适应性凝胶层允许将治疗相关药物递送到猪眼球的后段。我们的发现强调了在增加和延长眼表面接触和药物吸收之前,制剂应适应眼表面的重要性。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8de9/7655548/ec8a2a8624f6/nihms-1616906-f0006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8de9/7655548/33903cc36b94/nihms-1616906-f0001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8de9/7655548/a8ae8fa497a7/nihms-1616906-f0002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8de9/7655548/8189ffbca724/nihms-1616906-f0003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8de9/7655548/7074be0c52ae/nihms-1616906-f0004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8de9/7655548/e71388376662/nihms-1616906-f0005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8de9/7655548/ec8a2a8624f6/nihms-1616906-f0006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8de9/7655548/33903cc36b94/nihms-1616906-f0001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8de9/7655548/a8ae8fa497a7/nihms-1616906-f0002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8de9/7655548/8189ffbca724/nihms-1616906-f0003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8de9/7655548/7074be0c52ae/nihms-1616906-f0004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8de9/7655548/e71388376662/nihms-1616906-f0005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8de9/7655548/ec8a2a8624f6/nihms-1616906-f0006.jpg

相似文献

[1]
Gelling hypotonic polymer solution for extended topical drug delivery to the eye.

Nat Biomed Eng. 2020-11

[2]
Comparison of thermosensitive in situ gels and drug-resin complex for ocular drug delivery: In vitro drug release and in vivo tissue distribution.

Int J Pharm. 2020-2-26

[3]
Comparison of ion-activated in situ gelling systems for ocular drug delivery. Part 1: physicochemical characterisation and in vitro release.

Int J Pharm. 2011-3-29

[4]
Novel in situ gelling ophthalmic drug delivery system based on gellan gum and hydroxyethylcellulose: Innovative rheological characterization, in vitro and in vivo evidence of a sustained precorneal retention time.

Int J Pharm. 2019-11-6

[5]
Optimizing ophthalmic delivery of a poorly water soluble drug from an aqueous in situ gelling system.

Eur J Pharm Biopharm. 2020-9

[6]
In-situ forming gels containing fluorometholone-loaded polymeric nanoparticles for ocular inflammatory conditions.

Colloids Surf B Biointerfaces. 2018-11-27

[7]
In vitro and in vivo evaluation of in situ gelling systems for sustained topical ophthalmic delivery: state of the art and beyond.

Drug Discov Today. 2017-4

[8]
Terminalia arjuna gum/alginate in situ gel system with prolonged retention time for ophthalmic drug delivery.

Int J Biol Macromol. 2020-6-1

[9]
Sustained ocular delivery of brimonidine tartrate using ion activated in situ gelling system.

Curr Drug Deliv. 2012-3

[10]
Chitosan-Based In Situ Gels for Ocular Delivery of Therapeutics: A State-of-the-Art Review.

Mar Drugs. 2018-10-9

引用本文的文献

[1]
Pathology-inspired collagen-binding thermosensitive micelle drops enable prolonged and efficient treatment of fungal keratitis.

Bioact Mater. 2025-4-22

[2]
A highly mobile adeno-associated virus targeting vascular smooth muscle cells for the treatment of pulmonary arterial hypertension.

Nat Biomed Eng. 2025-4-29

[3]
Rapid forming PEG hydrogels for mucosal drug delivery.

Biomater Sci. 2025-4-17

[4]
Frontier applications of retinal nanomedicine: progress, challenges and perspectives.

J Nanobiotechnology. 2025-2-25

[5]
Hyaluronic acid conjugates with controlled oleic acid substitution as new nanomaterials for improving ocular co-delivery of cyclosporine A and oleic acid.

Asian J Pharm Sci. 2025-2

[6]
A Transformative Wearable Corneal Microneedle Patch for Efficient Therapy of Ocular Injury and Infection.

Adv Sci (Weinh). 2025-3

[7]
Wearable electrodriven switch actively delivers macromolecular drugs to fundus in non-invasive and controllable manners.

Nat Commun. 2025-1-2

[8]
Rapid in situ forming PEG hydrogels for mucosal drug delivery.

bioRxiv. 2024-8-19

[9]
Preparation and in vivo and ex vivo studies of sirolimus nano-in-situ gel ophthalmic formulation.

J Nanobiotechnology. 2024-7-16

[10]
Challenges and opportunities of developing small-molecule therapies for age-related macular degeneration.

Arch Pharm Res. 2024-6

本文引用的文献

[1]
Sustained delivery of acriflavine from the suprachoroidal space provides long term suppression of choroidal neovascularization.

Biomaterials. 2020-6

[2]
Sustained treatment of retinal vascular diseases with self-aggregating sunitinib microparticles.

Nat Commun. 2020-2-4

[3]
Species differences in ocular pharmacokinetics and pharmacological activities of regorafenib and pazopanib eye-drops among rats, rabbits and monkeys.

Pharmacol Res Perspect. 2019-11-20

[4]
Topical Drug Delivery to the Posterior Segment of the Eye: Addressing the Challenge of Preclinical to Clinical Translation.

Pharm Res. 2018-10-29

[5]
The Developing Regorafenib Eye drops for neovascular Age-related Macular degeneration (DREAM) study: an open-label phase II trial.

Br J Clin Pharmacol. 2018-11-25

[6]
TFOS DEWS II Diagnostic Methodology report.

Ocul Surf. 2017-7-20

[7]
Poloxamer-based thermoresponsive ketorolac tromethamine in situ gel preparations: Design, characterisation, toxicity and transcorneal permeation studies.

Eur J Pharm Biopharm. 2017-5

[8]
Topical dexamethasone γ-cyclodextrin nanoparticle eye drops increase visual acuity and decrease macular thickness in diabetic macular oedema.

Acta Ophthalmol. 2015-11

[9]
Particle tracking in drug and gene delivery research: State-of-the-art applications and methods.

Adv Drug Deliv Rev. 2015-8-30

[10]
Ocular drug delivery systems: An overview.

World J Pharmacol. 2013

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索